First Oral Antiviral for COVID-19, Lagevrio (Molnupiravir), Approved By MHRA
The Medicines and Healthcare products Regulatory Agency (MHRA) announced today that the antiviral Lagevrio (molnupiravir) is safe and effective at reducing the risk of hospitalisation and death in people with mild to moderate COVID-19 who are at increased risk of developing severe disease. This follows a rigorous review of its safety, quality and effectiveness by …
First Oral Antiviral for COVID-19, Lagevrio (Molnupiravir), Approved By MHRA Read More »